Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

Tubulis, reimagining antibody drug conjugates, led by Dr. Dominik Schumacher, Dr. Jonas Helma-Smets, Dr. Ingo Lehrke, Dr. Günter Fingerle-Rowson, MD, Dr. Björn Hock, Dr. Matthew Norkunas, and others, has secured €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT, and Seventure Partners. As part of the financing, Dr. Lorence Kim of Ascenta Capital and Patrick Heron of Frazier Life Sciences will join Tubulis’ Supervisory Board.

The Series C financing will support the clinical development of TUB-040, Tubulis’ lead ADC candidate targeting NaPi2b, overexpressed in ovarian cancer and lung adenocarcinomas. TUB-040 is in a Phase I/IIa study for platinum-resistant ovarian cancer and relapsed or refractory non-small cell lung cancer, and received FDA Fast Track designation in June 2024. The funding will also advance Tubulis’ pipeline, including TUB-030, preclinical programs, and expansion of its proprietary ADC platform to novel applications.

Tubulis’ landmark financing underscores strong investor confidence in the company and the potential of its ADC platforms. With TUB-040 progressing in clinical trials and initial data set to be presented at ESMO, the company is positioned to expand into earlier treatment lines while advancing its pipeline and technology platforms. The new funding enables Tubulis to continue developing differentiated antibody-drug conjugates tailored to solid tumor biology and designed to deliver enhanced therapeutic value.

The funding highlights the scientific strength and execution track record of the Tubulis team. With its unique ADC platform and experienced biotech investors supporting its growth, Tubulis is advancing toward demonstrating clinical impact and solidifying its position as a global leader in antibody-drug conjugates.